Dr. Reddy's Laboratories Ltd. ADR diskutieren
Dr. Reddy's Laboratories Ltd. ADR
WKN: 659157 / Symbol: RDY / Name: Dr. Reddy's / Aktie / Pharmazeutika / Mid Cap /
11,70 €
-3,31 %
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to an "underperform" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $75.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $81.00 to $87.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $16.90 price target on the stock, up previously from $14.44.
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
Ratings data for RDY provided by MarketBeat
Neueste Beiträge
BTIG_Research in Workday, Inc. diskutieren